Tag Archives: ISCO

3 Contenders To Be The First Profitable Stem Cell Company

By Ryan Pollack, SeekingAlpha.com

Every day is a day closer to a disease being treated, or even cured, by a stem cell therapy. The medical field is in a transition with clinical trials that are ongoing using adult, embryonic, and other forms of stem cells derived and differentiated using various laboratory techniques. These three companies have the potential to be the first self-sustaining, profitable regenerative medical companies.

See complete article at SeekingAlpha.com regarding Advanced Cell Technology (ACTC), Geron (GERN), and International Stem Cell Corporation (ISCO)

The Promising Cells Presented by International Stem Cell Corporation

Ken Aldrich of International Stem Cell Corporation (ISCO.OB) speaks on the latest research involving stem cell technology utilizing unfertilized eggs, as a basis for cell generation with a goal toward organ transplants which are immune to rejection by the body.

See complete article at the International Stem Cell Corporation blog

View from the Top – Kenneth Aldrich, International Stem Cell Corporation

Kenneth Aldrich, Chairman of International Stem Cell Corporation, discusses the next generation of therapeutic stem cells.

International Stem Cell Corporation Progresses towards Establishment of the Industry’s First Universal Stem Cell Bank, UniStemCell™

OCEANSIDE, Calif.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB: ISCO), www.internationalstemcell.com, announced today that it has signed up the first two in vitro fertilization (IVF) clinics and engaged an experienced pharmaceutical industry executive to lead the establishment of the company’s universal stem cell bank, UniStemCell™. International Stem Cell Corporation has made breakthrough stem cell discoveries that result in unique advantages over the only two other proven methods of making human pluripotent stem cells. In particular, for the first time in industry history, this will enable the establishment of a bank containing a manageable number of stem cell lines that will be immunological matches for large patient populations of different ethnic origin.

“By combining the proven oocyte retrieval experience and clinical excellence of California Center for Reproductive Medicine and Acacio Fertility Center with the pharmaceutical and operational experience of Dr. Craw, International Stem Cell Corporation is well positioned to generate the world’s first cGMP quality hpSC lines in 2010.”

The company uses unfertilized eggs (oocytes) to create human “parthenogenic” stem cells (hpSCs). Like embryonic stem cells (ESCs), hpSCs are pluripotent (i.e. have the capacity to become almost any cell type in the body), yet avoid ethical issues associated with use or destruction of viable human embryos. Unlike induced pluripotent stem cells (iPSs), hpSCs do not involve extensive gene manipulation, which may have unknown biological impact. Unlike both ESCs and iPSs, hpSCs can be created in a homozygous form such that each line will be an immunological match for millions of patients.

International Stem Cell Corporation has partnered with two IVF clinics in Southern California, California Center for Reproductive Medicine under the leadership of Dr. Lori Arnold and Acacio Fertility Center under the leadership of Dr. Brian Acacio. Both clinics provide exceptional clinical care for egg donors and IVF patients, not only regionally but across the US and abroad. California Center for Reproductive Medicine and Acacio Fertility Center provide a US source of oocytes under full regulatory and medical oversight that allow for the creation of the first clinical grade hpSC lines anywhere in the world. Dr. Acacio says: “We look forward to participating in this important research with the ultimate goal of each egg donation not only helping a single couple but millions of people with degenerative diseases.” Dr. Arnold says: “While we provide world-class care for our IVF patients, we are excited to add our clinical expertise and join International Stem Cell Corporation in this medical frontier of regenerative medicine.”

Click here for complete article.

International Stem Cell Corporation and Absorption Systems Announce Potential Stem Cell Alternative to Live Animal Testing for Corneal Damage

OCEANSIDE, Calif. & EXTON, Pa.–(BUSINESS WIRE)–International Stem Cell Corporation (OTCBB:ISCO)), the first company to perfect a method of creating human “parthenogenetic” stem cells from unfertilized eggs, announces positive results of its collaboration with Absorption Systems to study ISCO’s stem-cell-derived human corneal tissue as an alternative to live animals for drug testing. Initial results using non-animal or “in vitro” tests indicate an excellent correlation between the rates at which drugs pass through ISCO’s lab-grown corneal tissue and rabbit corneal tissue. The results offer great promise for reducing the use of living animals for eye safety testing. ISCO’s human corneal tissue is created from parthenogenetic stem cells in the laboratories of Lifeline Cell Technology (Walkersville, MD), ISCO’s wholly-owned subsidiary.

See Intlstemcell.blogspot.com for complete article.

Video – International Stem Cell Corporation CEO Ken Aldrich

International Stem Cell Corporation is a California company that has developed breakthrough human stem cell lines that promise to eliminate the rejection of transplanted cells by the patients immune system.

International Stem Cell Corporation Chairman and CEO Ken Aldrich

International Stem Cell Begins Pre-Clinical Testing of Its Parthenogenetic Stem Cells for Treatment of Retinal Disease

First Company To Grow Human Corneal Tissue From Stem Cells

Oceanside, California,  January 13, 2009 — International Stem Cell Corporation
(OTCBB: ISCO) has created layered human tissue from its unique parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa.

“Intact layers of retinal progenitor cells have been shown to restore lost visual responses in several retinal degeneration rodent models,” said Dr. Hans Keirstead, Co-Director of the Sue and Bill Gross Stem Cell Research Center at the University of California, Irvine.
“Thus, we are developing intact retinal layers derived from International Stem Cell’s human parthenogenetic stem cells which could become a sustainable, FDA-approved therapeutic supply for patients with retinal degenerative diseases.”

ISCO’s human parthenogenetic stem cells have the potential to treat human disease yet possess key medical and ethical advantages over other kinds of stem cell products. They can be matched to common immune types and thus reduce the chance of transplant rejection among large segments of the population. Because they are created from unfertilized human eggs, they do not require the destruction of human embryos.

“We are aggressively pushing forward safe treatments for human diseases using
parthenogenetic stem cells,” said Jeffrey Janus, President of International Stem Cell.

“If we are successful in this work, our next step is to manufacture this layered human tissue for further tests, including human trials. This illustrates the strengths of combining scientific collaborations with outside researchers such as Dr. Keirstead with ISCO’s science and cell manufacturing expertise.”

For more information, visit the ISCO website at: www.internationalstemcell.com